A study of trontinemab for early Alzheimer's disease
Part of Brain & nervous system, Mental health clinical trials.
This trial tests a new drug called trontinemab for people with early Alzheimer's disease. The goal is to see if it can help slow down memory and thinking problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be willing to complete all study tasks, including brain scans and tests, for the full length of the study.
- You should have a study partner (a friend or family member) who can help you with study visits.
- You must have a confirmed Alzheimer's disease process, shown by a special brain scan (amyloid PET) or a spinal fluid test.
- You must have mild memory or thinking problems (diagnosed as MCI or mild dementia due to Alzheimer's).
- Your memory test scores must be at a certain level (MMSE score of 22 or higher, and RBANS Delayed Memory Index of 85 or lower).
- You must not have other serious brain conditions, like a history of stroke, head injury, or brain tumor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called trontinemab in people with early symptomatic Alzheimer's disease. It aims to see if it can slow down memory and thinking problems.
This study tests an investigational drug, trontinemab, in people who are cognitively healthy but have a blood marker suggesting a high chance of developing Alzheimer's symptoms later. The goal is to see if the drug can delay or prevent memory loss.
This study tests an experimental medication called RO7568282 to see if it can slow down memory decline in people with early Alzheimer's disease. If you have early memory problems and a confirmed Alzheimer's-related brain change, you may be able to join.
This trial tests a new drug, RO7812653, in people with early symptomatic Alzheimer's disease (including mild cognitive impairment due to AD). The goal is to see if it is safe and how the body handles it.
This trial tests an investigational injection for people in the early stages of Alzheimer's. It aims to see if the drug can safely slow down memory loss and brain changes.
This trial tests a new medicine, VHB937, in people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow down memory loss and thinking problems.
Hear when a new Alzheimer’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.